444 related articles for article (PubMed ID: 29154989)
21. Acetylation of CCAR2 Establishes a BET/BRD9 Acetyl Switch in Response to Combined Deacetylase and Bromodomain Inhibition.
Rajendran P; Johnson G; Li L; Chen YS; Dashwood M; Nguyen N; Ulusan A; Ertem F; Zhang M; Li J; Sun D; Huang Y; Wang S; Leung HC; Lieberman D; Beaver L; Ho E; Bedford M; Chang K; Vilar E; Dashwood R
Cancer Res; 2019 Mar; 79(5):918-927. PubMed ID: 30643017
[TBL] [Abstract][Full Text] [Related]
22. Targeting LRP6: A new strategy for cancer therapy.
Xue W; Zhu B; Zhao K; Huang Q; Luo H; Shou Y; Huang Z; Guo H
Pharmacol Res; 2024 Jun; 204():107200. PubMed ID: 38710241
[TBL] [Abstract][Full Text] [Related]
23. Furanodiene enhances the anti-cancer effects of doxorubicin on ERα-negative breast cancer cells in vitro.
Zhong ZF; Qiang WA; Wang CM; Tan W; Wang YT
Eur J Pharmacol; 2016 Mar; 774():10-9. PubMed ID: 26607462
[TBL] [Abstract][Full Text] [Related]
24. Targeting cancer epigenetic pathways with small-molecule compounds: Therapeutic efficacy and combination therapies.
Wang Y; Xie Q; Tan H; Liao M; Zhu S; Zheng LL; Huang H; Liu B
Pharmacol Res; 2021 Nov; 173():105702. PubMed ID: 34102228
[TBL] [Abstract][Full Text] [Related]
25. OTX015 (MK-8628), a novel BET inhibitor, displays in vitro and in vivo antitumor effects alone and in combination with conventional therapies in glioblastoma models.
Berenguer-Daizé C; Astorgues-Xerri L; Odore E; Cayol M; Cvitkovic E; Noel K; Bekradda M; MacKenzie S; Rezai K; Lokiec F; Riveiro ME; Ouafik L
Int J Cancer; 2016 Nov; 139(9):2047-55. PubMed ID: 27388964
[TBL] [Abstract][Full Text] [Related]
26. The palladacycle, BTC2, exhibits anti-breast cancer and breast cancer stem cell activity.
Kimani S; Chakraborty S; Irene I; de la Mare J; Edkins A; du Toit A; Loos B; Blanckenberg A; Van Niekerk A; Costa-Lotufo LV; ArulJothi KN; Mapolie S; Prince S
Biochem Pharmacol; 2021 Aug; 190():114598. PubMed ID: 33979647
[TBL] [Abstract][Full Text] [Related]
27. Activation of ALDH1A1 in MDA-MB-468 breast cancer cells that over-express CYP2J2 protects against paclitaxel-dependent cell death mediated by reactive oxygen species.
Allison SE; Chen Y; Petrovic N; Zhang J; Bourget K; Mackenzie PI; Murray M
Biochem Pharmacol; 2017 Nov; 143():79-89. PubMed ID: 28756208
[TBL] [Abstract][Full Text] [Related]
28. Co-targeting BET bromodomain BRD4 and RAC1 suppresses growth, stemness and tumorigenesis by disrupting the c-MYC-G9a-FTH1axis and downregulating HDAC1 in molecular subtypes of breast cancer.
Ali A; Shafarin J; Unnikannan H; Al-Jabi N; Jabal RA; Bajbouj K; Muhammad JS; Hamad M
Int J Biol Sci; 2021; 17(15):4474-4492. PubMed ID: 34803511
[TBL] [Abstract][Full Text] [Related]
29. The ErbB/HER family of protein-tyrosine kinases and cancer.
Roskoski R
Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
[TBL] [Abstract][Full Text] [Related]
30. Doxorubicin as a fluorescent reporter identifies novel MRP1 (ABCC1) inhibitors missed by calcein-based high content screening of anticancer agents.
Sampson A; Peterson BG; Tan KW; Iram SH
Biomed Pharmacother; 2019 Oct; 118():109289. PubMed ID: 31401398
[TBL] [Abstract][Full Text] [Related]
31. Molecular Pathways: Targeting the PI3K Pathway in Cancer-BET Inhibitors to the Rescue.
Stratikopoulos EE; Parsons RE
Clin Cancer Res; 2016 Jun; 22(11):2605-10. PubMed ID: 27250929
[TBL] [Abstract][Full Text] [Related]
32. Bromodomain and Extraterminal (BET) protein inhibition suppresses tumor progression and inhibits HGF-MET signaling through targeting cancer-associated fibroblasts in colorectal cancer.
Wen D; Wang Y; Zhu Z; Huang Z; Cui L; Wu T; Liu CY
Biochim Biophys Acta Mol Basis Dis; 2020 Dec; 1866(12):165923. PubMed ID: 32800944
[TBL] [Abstract][Full Text] [Related]
33. Targeting BRD4 proteins suppresses the growth of NSCLC through downregulation of eIF4E expression.
Gao Z; Yuan T; Zhou X; Ni P; Sun G; Li P; Cheng Z; Wang X
Cancer Biol Ther; 2018 May; 19(5):407-415. PubMed ID: 29333921
[TBL] [Abstract][Full Text] [Related]
34. Hitting two oncogenic machineries in cancer cells: cooperative effects of the multi-kinase inhibitor ponatinib and the BET bromodomain blockers JQ1 or dBET1 on human carcinoma cells.
Bauer K; Berger D; Zielinski CC; Valent P; Grunt TW
Oncotarget; 2018 May; 9(41):26491-26506. PubMed ID: 29899872
[TBL] [Abstract][Full Text] [Related]
35. Targeting oncogenic transcription factors by polyphenols: A novel approach for cancer therapy.
Rajagopal C; Lankadasari MB; Aranjani JM; Harikumar KB
Pharmacol Res; 2018 Apr; 130():273-291. PubMed ID: 29305909
[TBL] [Abstract][Full Text] [Related]
36. BET Inhibition as a Rational Therapeutic Strategy for Invasive Lobular Breast Cancer.
Walsh L; Haley KE; Moran B; Mooney B; Tarrant F; Madden SF; Di Grande A; Fan Y; Das S; Rueda OM; Dowling CM; Varešlija D; Chin SF; Linn S; Young LS; Jirström K; Crown JP; Bernards R; Caldas C; Gallagher WM; O'Connor DP; Ní Chonghaile T
Clin Cancer Res; 2019 Dec; 25(23):7139-7150. PubMed ID: 31409615
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-miR-125b interplay.
Abruzzese MP; Bilotta MT; Fionda C; Zingoni A; Soriani A; Vulpis E; Borrelli C; Zitti B; Petrucci MT; Ricciardi MR; Molfetta R; Paolini R; Santoni A; Cippitelli M
J Hematol Oncol; 2016 Dec; 9(1):134. PubMed ID: 27903272
[TBL] [Abstract][Full Text] [Related]
38. BET Bromodomain Inhibition as a Therapeutic Strategy in Ovarian Cancer by Downregulating FoxM1.
Zhang Z; Ma P; Jing Y; Yan Y; Cai MC; Zhang M; Zhang S; Peng H; Ji ZL; Di W; Gu Z; Gao WQ; Zhuang G
Theranostics; 2016; 6(2):219-30. PubMed ID: 26877780
[TBL] [Abstract][Full Text] [Related]
39. Bromodomain inhibitors, JQ1 and I-BET 762, as potential therapies for pancreatic cancer.
Leal AS; Williams CR; Royce DB; Pioli PA; Sporn MB; Liby KT
Cancer Lett; 2017 May; 394():76-87. PubMed ID: 28254412
[TBL] [Abstract][Full Text] [Related]
40. Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC).
Welti J; Sharp A; Yuan W; Dolling D; Nava Rodrigues D; Figueiredo I; Gil V; Neeb A; Clarke M; Seed G; Crespo M; Sumanasuriya S; Ning J; Knight E; Francis JC; Hughes A; Halsey WS; Paschalis A; Mani RS; Raj GV; Plymate SR; Carreira S; Boysen G; Chinnaiyan AM; Swain A; de Bono JS;
Clin Cancer Res; 2018 Jul; 24(13):3149-3162. PubMed ID: 29555663
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
